Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: From bench to bedside

Journal of Biochemistry

Volumn 158, Issue 3, 2015, Pages 173-179

  Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

DMARD; JAK inhibitor remission; rheumatoid arthritis.

Indexed keywords

ADALIMUMAB; JANUS KINASE INHIBITOR; METHOTREXATE; PLACEBO; STAT1 PROTEIN; TOFACITINIB; JAK1 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 3; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; STAT1 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA;

B LYMPHOCYTE ACTIVATION; CD4+ T LYMPHOCYTE; DENDRITIC CELL; DRUG CARCINOGENICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GENE; HEMATOLOGIC DISEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION; KIDNEY DISEASE; LIVER DISEASE; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; REVIEW; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BIOSYNTHESIS; GENETICS; INFLAMMATION; PATHOLOGY; TRANSLATIONAL RESEARCH;

ARTHRITIS, RHEUMATOID; HUMANS; INFLAMMATION; JANUS KINASE 1; JANUS KINASE 3; METHOTREXATE; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; PYRROLES; STAT1 TRANSCRIPTION FACTOR; TRANSLATIONAL MEDICAL RESEARCH; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84949552693     PISSN: 0021924X     EISSN: 17562651     Source Type: Journal    
DOI: 10.1093/jb/mvv069     Document Type: Review

References (31)

1. Burmester, G.R., Kivitz, A.J., Kupper, H., Arulmani, U., Florentinus, S., Goss, S.L., Rathmann, S.S., and Fleischmann, R.M. (2015) Efficacy and safety of ascending methotrexate dose in combination with adalimumab: The randomised CONCERTO trial. Ann. Rheum. Dis. 74, 1037-1044
2. Furst, D.E. and Emery, P. (2014) Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-Associated cell targets. Rheumatology 53, 1560-1569
3. McInnes, I.B. and Schett, G. (2011) The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205-2219
4. Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham, C.O. III, Birnbaum, N.S., Burmester, G.R., Bykerk, V.P., Cohen, M.D., Combe, B., Costenbader, K.H., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J.M., Hobbs, K., Huizinga, T.W., Kavanaugh, A., Kay, J., Kvien, T.K., Laing, T., Mease, P., Menard, H.A., Moreland, L.W., Naden, R.L., Pincus, T., Smolen, J.S., Stanislawska-Biernat, E., Symmons, D., Tak, P.P., Upchurch, K.S., Vencovsky, J., Wolfe, F., and Hawker, G. (2010) 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569-2581
5. Smolen, J.S., Aletaha, D., Bijlsma, J.W., Breedveld, F.C., Boumpas, D., Burmester, G., Combe, B., Cutolo, M., de Wit, M., Dougados, M., Emery, P., Gibofsky, A., Gomez-Reino, J.J., Haraoui, B., Kalden, J., Keystone, E.C., Kvien, T.K., McInnes, I., Martin-Mola, E., Montecucco, C., Schoels, M., and van der Heijde, D. (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631-637
6. D'Aura Swanson, C., Paniagua, R.T., Lindstrom, T.M., and Robinson, W.H. (2009) Tyrosine kinases as targets for the treatment of rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 317-324
7. Walker, J.G., Ahern, M.J., Coleman, M., Weedon, H., Papangelis, V., Beroukas, D., Roberts-Thomson, P.J., and Smith, M.D. (2007) Characterisation of a dendritic cell subset in synovial tissue which strongly expresses Jak/STAT transcription factors from patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 992-999
8. Macchi, P., Villa, A., Giliani, S., Sacco, M.G., Frattini, A., Porta, F., Ugazio, A.G., Johnston, J.A., Candotti, F., O'Shea, J.J., Vezzonl, P., Notarangelo, L.D. (1995) Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 377, 65-68
9. Pesu, M., Laurence, A., Kishore, N., Zwillich, S.H., Chan, G., and O'Shea, J.J. (2008) Therapeutic targeting of Janus kinases. Immunol. Rev. 223, 132-142
10. Tanaka, Y. and Yamaoka, K. (2013) JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod. Rheumatol. 23, 415-424
11. O'Shea, J.J., Kontzias, A., Yamaoka, K., Tanaka, Y., and Laurence, A. (2013) Janus kinase inhibitors in autoimmune diseases. Ann. Rheum. Dis. 72(Suppl 2)), ii111-ii115
12. Changelian, P.S., Flanagan, M.E., Ball, D.J., Kent, C.R., Magnuson, K.S., Martin, W.H., Rizzuti, B.J., Sawyer, P.S., Perry, B.D., Brissette, W.H., McCurdy, S.P., Kudlacz, E.M., Conklyn, M.J., Elliott, E.A., Koslov, E.R., Fisher, M.B., Strelevitz, T.J., Yoon, K., Whipple, D.A., Sun, J., Munchhof, M.J., Doty, J.L., Casavant, J.M., Blumenkopf, T.A., Hines, M., Brown, M.F., Lillie, B.M., Subramanyam, C., Shang-Poa, C., Milici, A.J., Beckius, G.E., Moyer, J.D., Su, C., Woodworth, T.G., Gaweco, A.S., Beals, C.R., Littman, B.H., Fisher, D.A., Smith, J.F., Zagouras, P., Magna, H.A., Saltarelli, M.J., Johnson, K.S., Nelms, L.F., Des Etages, S.G., Hayes, L.S., Kawabata, T.T., Finco-Kent, D., Baker, D.L., Larson, M., Si, M.S., Paniagua, R., Higgins, J., Holm, B., Reitz, B., Zhou, Y.J., Morris, R.E., O'Shea, J.J., and Borie, D.C. (2003) Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 302, 875-878
13. Flanagan, M.E., Blumenkopf, T.A., Brissette, W.H., Brown, M.F., Casavant, J.M., Shang-Poa, C., Doty, J.L., Elliott, E.A., Fisher, M.B., Hines, M., Kent, C., Kudlacz, E.M., Lillie, B.M., Magnuson, K.S., McCurdy, S.P., Munchhof, M.J., Perry, B.D., Sawyer, P.S., Strelevitz, T.J., Subramanyam, C., Sun, J., Whipple, D.A., and Changelian, P.S. (2010) Discovery of CP-690, 550: A potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J. Med. Chem. 53, 8468-8484
14. Karaman, M.W., Herrgard, S., Treiber, D.K., Gallant, P., Atteridge, C.E., Campbell, B.T., Chan, K.W., Ciceri, P., Davis, M.I., Edeen, P.T., Faraoni, R., Floyd, M., Hunt, J.P., Lockhart, D.J., Milanov, Z.V., Morrison, M.J., Pallares, G., Patel, H.K., Pritchard, S., Wodicka, L.M., and Zarrinkar, P.P. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132
15. Williams, N.K., Bamert, R.S., Patel, O., Wang, C., Walden, P.M., Wilks, A.F., Fantino, E., Rossjohn, J., and Lucet, I.S. (2009) Dissecting specificity in the Janus kinases: The structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 387, 219-232
16. Ghoreschi, K., Jesson, M.I., Li, X., Lee, J.L., Ghosh, S., Alsup, J.W., Warner, J.D., Tanaka, M., Steward-Tharp, S.M., Gadina, M., Thomas, C.J., Minnerly, J.C., Storer, C.E., LaBranche, T.P., Radi, Z.A., Dowty, M.E., Head, R.D., Meyer, D.M., Kishore, N., and O'Shea, J.J. (2011) Modulation of innate and adaptive immune responses by tofacitinib (CP-690, 550). J. Immunol. 186, 4234-4243
17. Maeshima, K., Yamaoka, K., Kubo, S., Nakano, K., Iwata, S., Saito, K., Ohishi, M., Miyahara, H., Tanaka, S., Ishii, K., Yoshimatsu, H., and Tanaka, Y. (2012) The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells. Arthritis Rheum. 64, 1790-1798
18. Kubo, S., Yamaoka, K., Kondo, M., Yamagata, K., Zhao, J., Iwata, S., and Tanaka, Y. (2014) The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann. Rheum. Dis. 73, 2192-2198
19. Wang, S.P., Iwata, S., Nakayamada, S., Niiro, H., Jabbarzadeh-Tabrizi, S., Kondo, M., Kubo, S., Yoshikawa, M., and Tanaka, Y. (2015) Amplification of IL-21 signalling pathway through Bruton's tyrosine kinase in human B cell activation. Rheumatology 54, 1488-1497
20. Borie, D.C., Larson, M.J., Flores, M.G., Campbell, A., Rousvoal, G., Zhang, S., Higgins, J.P., Ball, D.J., Kudlacz, E.M., Brissette, W.H., Elliott, E.A., Reitz, B.A., and Changelian, P.S. (2005) Combined use of the JAK3 inhibitor CP-690, 550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates. Transplantation 80, 1756-1764
21. Rousvoal, G., Si, M.S., Lau, M., Zhang, S., Berry, G.J., Flores, M.G., Changelian, P.S., Reitz, B.A., and Borie, D.C. (2006) Janus kinase 3 inhibition with CP-690, 550 prevents allograft vasculopathy. Transpl. Int. 19, 1014-1021
22. Tanaka, Y., Suzuki, M., Nakamura, H., Toyoizumi, S., and Zwillich, S.H. (2011) Phase II study of tofacitinib (CP-690, 550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res. 63, 1150-1158
23. Fleischmann, R., Cutolo, M., Genovese, M.C., Lee, E.B., Kanik, K.S., Sadis, S., Connell, C.A., Gruben, D., Krishnaswami, S., Wallenstein, G., Wilkinson, B.E., and Zwillich, S.H. (2012) Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum. 64, 617-629
24. Fleischmann, R., Kremer, J., Cush, J., Schulze-Koops, H., Connell, C.A., Bradley, J.D., Gruben, D., Wallenstein, G.V., Zwillich, S.H., and Kanik, K.S. (2012) Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495-507
25. Kremer, J., Li, Z.G., Hall, S., Fleischmann, R., Genovese, M., Martin-Mola, E., Isaacs, J.D., Gruben, D., Wallenstein, G., Krishnaswami, S., Zwillich, S.H., Koncz, T., Riese, R., and Bradley, J. (2013) Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: A randomized trial. Ann. Intern. Med. 159, 253-261
26. Lee, E.B., Fleischmann, R., Hall, S., Wilkinson, B., Bradley, J.D., Gruben, D., Koncz, T., Krishnaswami, S., Wallenstein, G.V., Zang, C., Zwillich, S.H., and van Vollenhoven, R.F. (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370, 2377-2386
27. van Vollenhoven, R.F., Fleischmann, R., Cohen, S., Lee, E.B., Garcia Meijide, J.A., Wagner, S., Forejtova, S., Zwillich, S.H., Gruben, D., Koncz, T., Wallenstein, G.V., Krishnaswami, S., Bradley, J.D., and Wilkinson, B. (2012) Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508-519
28. van der Heijde, D., Tanaka, Y., Fleischmann, R., Keystone, E., Kremer, J., Zerbini, C., Cardiel, M.H., Cohen, S., Nash, P., Song, Y.W., Tegzova, D., Wyman, B.T., Gruben, D., Benda, B., Wallenstein, G., Krishnaswami, S., Zwillich, S.H., Bradley, J.D., and Connell, C.A. (2013) Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 65, 559-570
29. Sonomoto, K., Yamaoka, K., Kubo, S., Hirata, S., Fukuyo, S., Maeshima, K., Suzuki, K., Saito, K., and Tanaka, Y. (2014) Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology 53, 914-918
30. Keystone, E.C., Taylor, P.C., Drescher, E., Schlichting, D.E., Beattie, S.D., Berclaz, P.Y., Lee, C.H., Fidelus-Gort, R.K., Luchi, M.E., Rooney, T.P., Macias, W.L., and Genovese, M.C. (2015) Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann. Rheum. Dis. 74, 333-340
31. Kontzias, A., Kotlyar, A., Laurence, A., Changelian, P., and O'Shea, J.J. (2012) Jakinibs: A new class of kinase inhibitors in cancer and autoimmune disease. Curr. Opin. Pharmacol. 12, 464-470